Peapack Gladstone Financial Corp Has $57.22 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Peapack Gladstone Financial Corp boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 74,119 shares of the company's stock after acquiring an additional 492 shares during the quarter. Eli Lilly and Company comprises about 0.8% of Peapack Gladstone Financial Corp's investment portfolio, making the stock its 29th biggest position. Peapack Gladstone Financial Corp's holdings in Eli Lilly and Company were worth $57,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of LLY. CWA Asset Management Group LLC grew its holdings in Eli Lilly and Company by 11.9% during the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after purchasing an additional 724 shares during the last quarter. Centerpoint Advisory Group purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $514,000. M&T Bank Corp grew its position in Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after buying an additional 1,867 shares during the period. Kentucky Trust Co purchased a new position in Eli Lilly and Company during the fourth quarter valued at $834,000. Finally, Proficio Capital Partners LLC raised its position in shares of Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after buying an additional 1,562 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several brokerages have recently issued reports on LLY. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research note on Tuesday. Citigroup dropped their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Finally, Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $1,018.89.

Eli Lilly and Company Trading Up 0.5 %

Shares of NYSE LLY traded up $3.45 during mid-day trading on Tuesday, hitting $727.18. 2,746,567 shares of the company traded hands, compared to its average volume of 3,336,718. The business has a 50 day moving average of $846.64 and a two-hundred day moving average of $830.05. The stock has a market capitalization of $689.49 billion, a price-to-earnings ratio of 62.12, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.